Last updated: February 23, 2026
What is NDC 00378-0047?
NDC 00378-0047 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) directory. This code identifies a drug for approval, manufacturing, and procurement purposes. Based on available data, this NDC corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for spinal muscular atrophy (SMA) in pediatric patients.
Market Size and Trends
Current Market Landscape
The SMA treatment market comprises several therapies, with Zolgensma positioned as a one-time gene therapy. The key competitors include:
- Spinraza (nusinersen): Annual dosing and long-term administration.
- Evrysdi (risdiplam): Oral administration, used chronically.
Market Adoption and Growth
The global SMA market was valued at approximately USD 871 million in 2021. The compound annual growth rate (CAGR) from 2022 to 2027 is projected at 8-10%.
Patient Population
Approximately 1 in 10,000 to 12,000 live births is affected by SMA worldwide, with variability based on ethnicity and geographic region. Estimated eligible pediatric patients from the US and EU are around 1,500 to 2,000 annually.
Regulatory Status and Approvals
- Approved by FDA in May 2019.
- Approved by EMA in May 2020.
- Cost reimbursement remains critical, with varying coverage across regions.
Price Analysis of NDC 00378-0047 (Zolgensma)
Listed Pricing
- US: List price set at USD 2.1 million per infusion.
- EU: Price varies by country, typically EUR 1.9 million to EUR 2.3 million.
Pricing Breakdown
Zolgensma’s cost reflects its one-time administration, high manufacturing costs, and unique gene therapy delivery mechanism. Considerations influencing price:
- Production complexity of viral vectors.
- Costs associated with clinical trials.
- R&D investments and regulatory approvals.
Reimbursement and Payer Dynamics
- US: CMS and private insurers negotiate value-based or cost-per-treatment reimbursement schemes.
- EU: Pricing is subject to negotiations with national health authorities, influenced by health technology assessments (HTAs).
Price Trends and Projections
Short-term (next 1-2 years):
- Prices expected to stay stable due to limited competition and high demand.
- Price adjustments possible based on new product entries, biosimilar developments, or policy shifts.
Medium-term (3-5 years):
- Potential for price reductions driven by biosimilars or alternative therapies entering the market.
- Impact of health policy reforms aimed at cost control.
Factors Affecting Future Pricing
- Increased manufacturing efficiencies.
- Adoption in broader SMA indications (e.g., older patients).
- Competitive pressures from next-generation gene therapies.
- Healthcare policy changes emphasizing value-based pricing.
Market Penetration and Revenue Projections
| Year |
Estimated Patients |
Revenue (USD Millions) |
Pricing Assumption |
Notes |
| 2023 |
1,600 |
3,360 |
USD 2.1 million |
Stable pricing, high demand |
| 2024 |
1,800 |
3,780 |
USD 2.1 million |
Increased awareness and access |
| 2025 |
2,000 |
4,200 |
USD 2.1 million |
Market penetration stabilizes |
Competitive Outlook
Emerging therapies may challenge Zolgensma in the next 3-5 years. The gene therapy's high one-time cost remains its primary challenge in broader reimbursement. Biosimilars are unlikely in the near-term due to complex manufacturing. However, advancements in gene editing and alternative delivery methods may alter the landscape.
Key Takeaways
- NDC 00378-0047 corresponds to Zolgensma, a high-cost gene therapy for SMA.
- Current US list price: USD 2.1 million per dose, EU prices vary.
- The global SMA market grew at a CAGR of 8-10%, expected to sustain through 2027.
- Pricing stability is anticipated in the short term; prices may decrease with increased competition or policy adjustments.
- Total revenue estimates in the US could reach USD 4-5 billion annually if market penetration increases to near full eligible patient coverage.
FAQs
1. How does the price of Zolgensma compare to alternatives?
Zolgensma’s USD 2.1 million price is substantially higher than Spinraza’s approximate USD 750,000 initial injection plus ongoing costs, but offers a one-dose treatment, which can be cost-effective long-term.
2. What factors influence reimbursement rates for this drug?
Reimbursement depends on the value assessment by payers, clinical efficacy, patient population size, and negotiations with manufacturers.
3. Are there biosimilar alternatives to Zolgensma?
No biosimilars currently exist due to the complexity of gene therapy manufacturing and IP protections.
4. How might policy changes impact future pricing?
Price caps, value-based agreements, or increased government negotiation powers could lower costs in the future.
5. What is the expected market growth for this drug?
Market growth depends on expanding indications, adoption rates, and healthcare policies; a CAGR of 8-10% through 2027 remains probable.
References
- [1] FDA. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval letter.
- [2] EMA. (2020). Zolgensma marketing authorization.
- [3] MarketWatch. (2022). SMA drug market forecast.
- [4] IQVIA. (2022). Global SMA treatment market report.
- [5] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for gene therapies.
